Director/PDMR Shareholding

RNS Number : 7375Z

GlaxoSmithKline PLC

16 March 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr M M Slaoui
b)	Position/status	Chairman, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	GlaxoSmithKline plc American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	An increase of 4 ADSs following the notional allocation of ADSs on 15 March 2017, at a price of $42.00 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.00 4
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-03-15
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr K Slaoui
b)	Position/status	PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	GlaxoSmithKline plc American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	An increase of 91 ADSs following the notional allocation of ADSs on 15 March 2017, at a price of $42.00 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.00 91
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-03-15
f)	Place of the transaction	n/a

 

END

 

 

DSHQQLFFDXFFBBF